Karyopharm Therapeutics Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; unaudited consolidated financial statements. Karyopharm is a clinical-stage drug developer focused on SINE compounds targeting XPO1. Its lead candidate, selinexor, was in clinical trials; the company had no drug sales.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data.
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Contract and grant revenue | $0 | $0.171 |
| Research and development expense | $20.751 | $10.979 |
| General and administrative expense | $5.399 | $2.904 |
| Operating loss | $(26.150) | $(13.712) |
| Net loss | $(26.067) | $(13.694) |
| Basic and diluted net loss per share | $(0.74) | $(0.46) |
| Cash used in operating activities | $(20.225) | $(10.569) |
- At March 31, cash and cash equivalents were $51.453 million, short- and long-term investments totaled $233.495 million, and restricted cash was $0.400 million: $285.348 million in aggregate liquidity resources.
- Total assets were $292.040 million and total liabilities were $16.515 million. The balance sheet reports no debt; liabilities primarily comprised payables, accruals, and deferred rent.
- Stockholders’ equity was $275.525 million. The company had 35.687 million common shares outstanding at quarter-end.
- No product gross margin was reported; product sales had not begun.
Changes versus the prior-year quarter
- Net loss increased 90% to $26.067 million, while operating expenses rose to $26.150 million from $13.883 million.
- R&D expense increased 89%, mainly from higher clinical-trial and CRO costs, selinexor manufacturing, increased personnel, and preclinical work. G&A expense increased 86%, principally due to personnel and stock-based compensation.
- Operating cash use nearly doubled. Investing cash use was $170.080 million, mainly because the company purchased $184.902 million of investments and received $15.000 million from maturities; this largely reflects investment of funds rather than operating expenditure.
- The January 2015 public offering of 2.950 million shares generated approximately $90.830 million in net proceeds. Common shares outstanding increased from 32.699 million at December 31, 2014 to 35.687 million at March 31, 2015.
Outlook, commentary, and risks
- Management expected existing cash, cash equivalents, restricted cash, and investments to fund the current operating plan and capital spending into 2018, and expected to finish 2015 with more than $200 million in those resources. These are forward-looking estimates, not guarantees.
- The company expected expenses and operating losses to increase as clinical development expanded. It had initiated registration-directed selinexor trials in AML, Richter’s Transformation, and DLBCL, and planned trials in multiple myeloma in the first half of 2015 and liposarcoma in the second half.
- Management reported selinexor had been administered to more than 750 patients across company-sponsored Phase 1 and Phase 2 trials and described observed anti-cancer activity. The filing cautions that early or interim trial findings may not predict later results or establish safety and efficacy.
- Reported safety concerns included gastrointestinal events and fatigue; Grade 3 or 4 events most commonly included thrombocytopenia and neutropenia. The company also advised trial participants about potential worsening of pre-existing cataracts. Some serious adverse events were considered related to selinexor.
- Key risks include clinical or regulatory failure, trial delays or enrollment challenges, reliance on CROs and third-party manufacturers, competition, intellectual-property challenges, and the need for additional financing. The company stated it would need substantial additional funding over time and had no committed external funding source.
- There were no material changes to contractual obligations reported from the 2014 Form 10-K and no off-balance-sheet arrangements. Management concluded disclosure controls were effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Subsequent progress, enrollment, safety findings, and regulatory feedback for each selinexor registration-directed trial, including the planned multiple myeloma and liposarcoma programs.
- Whether actual operating cash use and investment balances remain consistent with management’s runway estimate into 2018 and its year-end 2015 liquidity expectation.
- Future financing needs and potential dilution, including share issuance and outstanding equity awards.
- Clinical-trial and manufacturing costs, and whether third-party providers can meet required timelines and quality standards.
- The filing’s reported adverse events and cataract warning, and how emerging safety data may affect the benefit-risk profile of selinexor.